Qiagen has received clearance from the US Food and Drug Administration (FDA) for the first in a planned series of gastrointestinal panels for clinical use. For use with the Netherlands-based ...

The 2025 clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral) covering five causes of gastrointestinal illness that are recommended by the Infectious Diseases ...

The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug Administration's clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers five ...

(RTTNews) - Qiagen (QGEN) announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. The clearance by the U.S. Food and Drug ...

--(BUSINESS WIRE)--Applied BioCode, a leader in molecular diagnostics panel testing, is excited to announce a significant enhancement to its BioCode ® Gastrointestinal Pathogen Panel ...

More than 90 passengers and crew members on a Royal Caribbean International cruise ship which set sail from Tampa, Florida, on Feb. 1 for a weeklong cruise came down with a gastrointestinal ...

For use with the Netherlands-based company’s QIAstat-Dx syndromic testing analyser, the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral) covers five causes of gastrointestinal ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. This clearance by ...